Papers

1

Total Citations

2

H-Index

1

About

Dr. T. Raveloarivahy is a leading clinical oncologist whose research focuses on optimizing treatment strategies for head and neck cancers, particularly oropharyngeal, supraglottic, and hypopharyngeal carcinomas. Their most notable contribution is the design and leadership of a pivotal Phase III study comparing the “best of” radiotherapy versus the “best of” trans-oral surgery (TOS) for patients with T1-T2, N0-N1 tumors. This work directly addresses a critical clinical dilemma: selecting between organ-preserving radiation and minimally invasive surgical approaches to maximize oncologic outcomes while minimizing functional morbidity. Although the trial protocol paper has garnered 2 citations, its significance lies in its potential to reshape standard-of-care guidelines by providing high-level evidence for individualized treatment decisions. Dr. Raveloarivahy’s research is instrumental in advancing precision oncology for early-stage head and neck cancers, bridging the gap between surgical and radiation oncology. Their ongoing efforts continue to influence multidisciplinary tumor board discussions and clinical trial design, underscoring a commitment to evidence-based, patient-centered care in a field where treatment de-escalation and quality of life are paramount.

Research Focus

Key Achievements

1
H-Index
1
Papers
2
Total Citations
2
Avg Citations/Paper
🏆 Most Cited Paper
706TiP Phase III study assessing the “best of” radiotherapy compared to the “best of” surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0-N1 oropharyngeal, supraglottic carcinoma and with T1, N0 hypopharyngeal carcinoma
2 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 18
🏛 Institutions: European Organisation for Research and Treatment of Cancer

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago